Table 1 CD3⁻ CD16⁺, CD3⁻ CD56⁺, CD3⁻ CD16⁺ CD56⁺ NK cells, CD3⁺ CD56⁺ NKT cells, and CD5⁺ CD19⁺ B cells percentage, IL-10 serum levels in IFN-treated RRMS, IFN-treated MS, NMOSD and HC groups

CD3⁻CD16⁺ CD56⁺

1.81 \(\pm\) 0.87

4.74 \(\pm\) 1.80

4.64 \(\pm\) 1.26

5.83 \(\pm\) 2.19

 < 0.0001

CD3⁻CD16⁺

3.13 \(\pm\) 1.49

7.62 \(\pm\) 3.23

5.91 \(\pm\) 2.50

8.28 \(\pm\) 3.85

 < 0.0001

CD3⁻CD56⁺

4.73 \(\pm\) 2.63

13.31 \(\pm\) 5.67

11.23 \(\pm\) 4.76

13.49 \(\pm\) 7.51

 < 0.0007

CD3⁺CD56⁺

2.89 \(\pm\) 1.51

5.56 \(\pm\) 3.04

5.47 \(\pm\) 1.24

3.16 \(\pm\) 1.98

 < 0.002

CD5⁺CD19⁺ B cell

0.81 \(\pm\) 0.17

1.32 \(\pm\) 0.67

0.30 \(\pm\) 0.20

0.5 \(\pm\) 0.22

 < 0.0001

Serum level of IL-10 (pg/ml)

8.06 \(\pm\) 5.39

5.07 \(\pm\) 1.44

5.33 \(\pm\) 2.56

8.38 \(\pm\) 2.84

 < 0.003

Total number of attack in first two year

1.89(1–4)

2.5(1–5)

2.01(1–4)

–

N.S

Disease duration

5.6(0.4–13)

2.6(0.1–10)

6.6(1–17)

–

0.04

Age of disease onset

29.8(16–56)

25.6(12–44)

30.8(19–42)

–

N.S